Male breast cancer and mantle cell lymphoma in a single patient: A case report and literature review
Absract Rationale: Although still relatively rare, multiple primary malignant neoplasms (MPMNs) have been increasingly reported in recent years. Patient concerns and diagnoses: A 65-year-old man was referred to our hospital for a painless, incidental left axillary lump. Ultrasound showed enlarged left axillary lymph nodes. An excisional biopsy was conducted on 3 lymph nodes. The pathological diagnosis was determined to be metastatic adenocarcinoma and mantle cell lymphoma (MCL) in the lymph nodes. Further physical examination of the patient yielded a 1.5-cm hard, left subareolar mass. Interventions and outcomes: The patient underwent modified radical mastectomy. The diagnosis was grade II invasive ductal carcinoma (stage IIA). The axillary lymph node showed MCL (stage I, group A), but not metastatic ductal carcinoma. The patient received chemotherapy, including 6 courses of CHOP (A chemotherapy protocol consists of cyclophosphamide 1.2 g day 1, doxorubicin 80 mg day 1, vindesine 4 mg day1, and prednisone 90 mg from day 1 to 5) for lymphoma and breast cancer. The patient was also administered endocrine therapy. After a 54-month follow-up, the patient was well with no evidence of disease. Lessons: MPMNs are easily misdiagnosed as a primary and metastatic tumor, leading to delayed or erroneous treatment. Male breast cancer in a patient with MCL is rare. Early diagnosis and proper therapy are necessary for an optimal prognosis. Further studies are required to ...
(MedPage Today) -- Peter Ubel, MD, explains how to let older patients know tests won't help
A preplanned analysis of ctDNA found that a subpopulation of mCRC patients with acquired anti-EGFR resistance were sensitive to treatment with Sym004.
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.
Date: Wednesday, 03 21, 2018; Speaker: Charles Rabkin, M.D., Senior Investigator, Division of Cancer Epidemiology and Genetics, NCI; https://epi.grants.cancer.gov/events
Date: Thursday, 03 29, 2018; Speaker: Cassandra Harris, M.S., M.C.H.E.S., Manager, Health Education, MD Anderson Cancer Center; Kathi Ridley-Merriweather, M.A., Communications and Minority Outreach Coordinator, Komen Tissue Bank; Ren é Arnold, M.B.A., Former Operations Manager, The Fountain of Praise Church; https://epi.grants.cancer.gov/events/enrich-forum/
The Wayne D. Kuni&Joan E. Kuni Foundation has awarded $5 million to Legacy Health Foundation to found a cancer research project. The grant will fund research into how cancer can be targeted by manipulating adenosine kinase, an enzyme that controls cell growth. The research is led by Detlev Boison, Dow Chair of Neurology and director of neurobiology research and basic and translational research at Legacy Research Institute; and Dr. Serene Perkins, director of surgical and clinical research at…
Conclusion: LIPUS produces cytoprotective effects against oxidative injuries to endothelial cells through suppressing the oxidative stress-induced EndMT, activating the PI3K/AKT pathway under oxidative stress, and limiting cell migration and excessive ECM deposition.Cell Physiol Biochem 2018;45:1350 –1365
Cabozantinib showed significant antitumor activity in the treatment of differentiated thyroid cancer that progressed following surgery and radioactive iodine therapy, according to a new phase II study.
An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.
Oncologists need to play a larger role in discussing exercise with cancer survivors, and home-based exercise interventions offer advantages, say Australian researchers.Medscape Medical News